Longeveron Receives Intent to Grant Notice from the European Patent Office for Methods to Monitor Efficacy of Lomecel-B™ Cell Therapy Through Levels…


Issued claims will protect use of a biomarker to assess response to Lomecel-B™ in patients with blood vessel dysfunction Issued claims will protect use of a biomarker to assess response to Lomecel-B™ in patients with blood vessel dysfunction

View original post here:
Longeveron Receives Intent to Grant Notice from the European Patent Office for Methods to Monitor Efficacy of Lomecel-B™ Cell Therapy Through Levels...

Related Posts